This Acquirers Multiple Stock Is Undervalued, According to Dalio, Simons, Greenblatt

Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:

Gilead Sciences Inc (GILD)

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead’s acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead’s exposure to cell therapy and noncell therapy in oncology.

A quick look at the price chart below shows us that the stock is down 22.55% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 11.00 which means that it remains undervalued.

GILD data by YCharts

(Shares)

Jim Simons – 5,575,850

Cliff Asness – 3,864,176

Ray Dalio – 807,919

John Rogers – 749,740

Bernard Horn – 435,700

Joel Greenblatt – 95,422

Chuck Royce – 58,000